#### Introduction

Thank you for participating in the National Home Infusion Foundation's (NHIF) benchmarking initiatives. The information in this survey will be used to describe the sample population for benchmarking initiatives and to validate benchmarking procedures. Additionally, NHIF intends to publish an annual report of "Home Infusion Industry Trends" to describe how provider businesses are evolving as the healthcare environment changes.

#### **PRIVACY**

NHIF does not know the identities of the locations taking this survey, and all data will remain deidentified. There will be privacy in gathering, storing and handling of all the data and information collected by NHIF. In no circumstances will any of the data shared in this survey be traced back to your location or organization.

#### Preparing to complete the profile:

Each individual home infusion location that will submit data for benchmarking must be assigned a Data Participation Code (DPC) by Strategic Healthcare Programs (SHP). Never share your DPC with anyone outside of your organization as this code is essential to maintaining confidentiality. Contact Jennifer Lyons at jennifer.lyons@nhia.org to learn how to obtain your location DPC.

The Key Contact from each home infusion location is responsible for collecting and entering the data into this profile. Answer all of the questions in this survey to the best of your ability. Where exact numbers are not available, you may provide an estimate based on the best available data. A response is required to all questions in the survey.

#### **Definitions:**

For the purposes of responding to this survey, please refer to the following definitions of key terms:

Home Infusion - a therapy that is administered through an intravenous (IV) or subcutaneous (SC) catheter in the home setting.

Home Infusion Location - a single, separately licensed pharmacy that provides home infusion services.

Revenue - the net revenue after discounts and contractual adjustments from list price are applied.

Home care - the provision of Medicare certified nursing and other professional services such as home health aides, physical therapy, social work, etc.

Home health nursing - the provision of home nursing services without a pharmacy component.

Courier - a driver-based delivery service

Parcel Service - a mail or shipping service

(VER 4	-) Home	Infusion	Location	Profile

Loc	cation Data Participation Code
*	Do you have the Data Participation Code assigned to your location by SHP?  Yes
	No No

(VER 4-) Home Infusion Location	Profile
* 2. Enter the Data Participation Code (DPC) for your home infusion	location
	_

#### **Location Characteristics**

Location Characteristics	
* 3. Select the state where your home infusion pharm	acy is located.
* 4. Indicate the total <u>number</u> of states for which your provide home infusion services.	location maintains an active pharmacy license to
* 5. Select the category that best represents your local	ation's organizational structure.
Single-site organization not affiliated with a hospital or acceptance system	Franchise location not affiliated with a hospital or acute care system
Organization with multiple, commonly owned home infusion locations, not affiliated with a hospital or acute care system	
Comments	
* 6. How many years has your home infusion <u>location</u> Other (please specify)	been in operation?
* 7. Select the agencies below that are actively provide location. Mark all that apply.	
The Joint Commission (TJC)	Community Health Accreditation Partner (CHAP)
The Compliance Team (TCT)	Healthcare Quality Association on Accreditation (HQAA)
Accreditation Commission for Healthcare (ACHC)	National Association of Boards of Pharmacy (NABP)
Center for Pharmacy Practice Accreditation (CPPA)	Utilization Review Accreditation Commission (URAC)
Other (please specify)	

rvie	ce Characteristics		ī
:I VIC	ce Characteristics		
8. 5	Select the products and services provided I	y your home infusion location. Mark all that apply.	
	Home infusion (home administration of IV and cont subcutaneous medications)		
	Enteral therapy	Specialty oral medications (closed door)  Non-sterile compounded products	
	Durable medical equipment (other than enteral)	Non stelle compounded products	
	Retail pharmacy (open to walk-in customers)		
	Other (please specify)		
		ur home infusion location's combined <b>NET REVENUE</b> ted in the prior question. (I.e. Include revenue from se	
201		ted in the prior question. (I.e. Include revenue from se	
201	18 for <u>ALL</u> pharmacy-based services indicate than home infusion products such as information.	ted in the prior question. (I.e. Include revenue from seusion suites, enterals, injectables, etc.)	
201	18 for <u>ALL</u> pharmacy-based services indicater than home infusion products such as inf	ted in the prior question. (I.e. Include revenue from sousion suites, enterals, injectables, etc.)  \$20 Million to \$25 Million	
201	18 for <u>ALL</u> pharmacy-based services indicater than home infusion products such as inf 0 - \$1 Million \$1 Million to \$2.5 Million	ted in the prior question. (I.e. Include revenue from secusion suites, enterals, injectables, etc.)  \$20 Million to \$25 Million  \$25 Million to \$30 Million	
201	18 for ALL pharmacy-based services indicater than home infusion products such as inf 0 - \$1 Million \$1 Million to \$2.5 Million \$2.5 to \$5 Million	ted in the prior question. (I.e. Include revenue from secusion suites, enterals, injectables, etc.)  \$20 Million to \$25 Million  \$25 Million to \$30 Million  \$30 Million to \$35 Million	
201	18 for ALL pharmacy-based services indicater than home infusion products such as inf 0 - \$1 Million \$1 Million to \$2.5 Million \$2.5 to \$5 Million \$5 Million to \$10 Million	ted in the prior question. (I.e. Include revenue from secusion suites, enterals, injectables, etc.)  \$20 Million to \$25 Million  \$25 Million to \$30 Million  \$30 Million to \$35 Million  \$35 Million to \$40 Million	
201	18 for ALL pharmacy-based services indicater than home infusion products such as inf 0 - \$1 Million \$1 Million to \$2.5 Million \$2.5 to \$5 Million \$5 Million to \$10 Million \$10 Million to \$15 Million	ted in the prior question. (I.e. Include revenue from secusion suites, enterals, injectables, etc.)  \$20 Million to \$25 Million  \$25 Million to \$30 Million  \$30 Million to \$35 Million  \$35 Million to \$40 Million	
201	18 for ALL pharmacy-based services indicater than home infusion products such as inf 0 - \$1 Million \$1 Million to \$2.5 Million \$2.5 to \$5 Million \$5 Million to \$10 Million \$10 Million to \$20 Million	ted in the prior question. (I.e. Include revenue from secusion suites, enterals, injectables, etc.)  \$20 Million to \$25 Million  \$25 Million to \$30 Million  \$30 Million to \$35 Million  \$35 Million to \$40 Million	
201	18 for ALL pharmacy-based services indicater than home infusion products such as inf 0 - \$1 Million \$1 Million to \$2.5 Million \$2.5 to \$5 Million \$5 Million to \$10 Million \$10 Million to \$20 Million	ted in the prior question. (I.e. Include revenue from secusion suites, enterals, injectables, etc.)  \$20 Million to \$25 Million  \$25 Million to \$30 Million  \$30 Million to \$35 Million  \$35 Million to \$40 Million	
201	18 for ALL pharmacy-based services indicater than home infusion products such as inf 0 - \$1 Million \$1 Million to \$2.5 Million \$2.5 to \$5 Million \$5 Million to \$10 Million \$10 Million to \$20 Million	ted in the prior question. (I.e. Include revenue from secusion suites, enterals, injectables, etc.)  \$20 Million to \$25 Million  \$25 Million to \$30 Million  \$30 Million to \$35 Million  \$35 Million to \$40 Million	
201	18 for ALL pharmacy-based services indicater than home infusion products such as inf 0 - \$1 Million \$1 Million to \$2.5 Million \$2.5 to \$5 Million \$5 Million to \$10 Million \$10 Million to \$20 Million	ted in the prior question. (I.e. Include revenue from secusion suites, enterals, injectables, etc.)  \$20 Million to \$25 Million  \$25 Million to \$30 Million  \$30 Million to \$35 Million  \$35 Million to \$40 Million	

(VER 4-) Home Infusion Location Profile			
umps			
10. Which of the following a	nbulatory infusion pumps do you use in your location? Mark all that apply.		
CADD VIP	Graseby 2000 Syringe Pump		
CADD PCA	Bard 150XL		
CADD Solis	Bard 300XL		
Curlin 4000 series	Freedom 60		
Curlin 6000 series	Freedom Edge		
Alaris	Our location does not use ambulatory infusion pumps		
Bard Harvard Mini-infuser			
Other (please specify)			
	GE of ambulatory home infusion pumps that are rented versus owned by yone ne nearest 5%. The sum of the combined answers must be 100.		
location. Round answer to			
location. Round answer to			
location. Round answer to  Rented  Owned			
location. Round answer to  Rented  Owned			
location. Round answer to  Rented  Owned			
location. Round answer to  Rented  Owned			
location. Round answer to  Rented  Owned			
location. Round answer to  Rented  Owned			
location. Round answer to  Rented  Owned			
location. Round answer to  Rented  Owned			
location. Round answer to  Rented  Owned			
location. Round answer to  Rented  Owned			

(VER 4-) Home Infusion Location Profile	
Infusion Suites	
* 12. Do you have an infusion suite at your home infusion location?	
Yes	
○ No	

(VER 4-) Home Infusion Location Profile
Infusion Suite Characteristics
* 13. How many chairs are provided in your location's infusion suite?
Other (please specify)
* 14. How many unique patients were served in your location's infusion suite in 2018?

(VER 4-) Home Infusion Location Profile			
ursing Services			
* 15. Describe how home infusion nursing services	are provided by your location.		
We exclusively use nurses who are directly employed by home infusion location to provide in-home nursing service			
We exclusively sub-contract and/or coordinate with home health agencies to provide in-home nursing services.	e		
Comment:			
* 16. For the most recently completed fiscal quarter, provided under each of the scenarios listed below.	indicate the <b>PERCENTAGE</b> of in-home nursing visits		
Enter "0" if no nursing visits are provided by the list. 100.	sted scenario. The sum of the combined answers must be		
Directly employed nurses	70		
Sub-contracted arrangement with a home health agency			
In coordination with a home care agency that bills directly for in-home visits			
* 17. Which of the following catheter insertion service your location? Mark all that apply.  Midline insertion	ces are you able to provide through nurses employed by		
PICC insertion			
Peripheral line insertion			
We do not directly employ nurses who provide these ser	vices.		
Comments			

(VER 4-) Home I	Infusion Location Profile
Deliveries	
* 18. For the most recently completed fiscal quar	ter, indicate the <b>PERCENTAGE</b> of deliveries made by each
of the following methods. Answers must add up utilize a particular delivery service.	to 100%. Enter "0" if your home infusion location does not
utilize a particular delivery service.	%
Drivers employed by the home infusion location	
Contracted local courier service	
Private parcel services	
such as FedEx and UPS  Nurses	
United States Postal	
Service (USPS)	
Other	
Comments	

### Revenue Characteristics

infused in the home s	mbined <u>NET REVENUE</u> for the most recently completed <u>fiscal quart</u> etting? Include all <u>revenue associated with acute and specialty</u> ound to the nearest 1,000.)	<u>er</u> for therapies
<u>Do not</u> include self-inj	ectable, enteral revenue or other non-infused products or services.	
	ME INFUSION REVENUE billed in the most recent fiscal quarter for pries. Round to the nearest 1,000.	each of the
Do not include entera	ls, infusion suites, or self-injectable revenue.	
Medicare Part B		
Medicare Part D		
Medicare HMO/Advantage		
State Medicaid Programs		
Workman's Compensation		
Commercial Insurance		
Charity/No Payer		
Patient self-pay		
Other		

(VER 4-)	) Home	Infusion	Location	Profile
----------	--------	----------	----------	---------

Therapy [	Detail
-----------	--------

Immune globulin - IV  Immune globulin - SC  Bleeding disorder  Biologics - Other (monoclonal antibodies, biosimilars, enzymes)  Catheter care  Other (non-biologic, e.g.	Hydration  Pain management  Inotropic  Antineoplastic chemotherapy  Immune globulin - IV  Immune globulin - SC  Bleeding disorder  Biologics - Other (monoclonal antibodies,	
Pain management  Inotropic  Antineoplastic chemotherapy  Immune globulin - IV  Immune globulin - SC  Bleeding disorder  Biologics - Other (monoclonal antibodies, biosimilars, enzymes)  Catheter care  Other (non-biologic, e.g.	Pain management  Inotropic  Antineoplastic chemotherapy  Immune globulin - IV  Immune globulin - SC  Bleeding disorder  Biologics - Other (monoclonal antibodies,	
Pain management  Inotropic  Antineoplastic chemotherapy  Immune globulin - IV  Immune globulin - SC  Bleeding disorder  Biologics - Other (monoclonal antibodies, biosimilars, enzymes)  Catheter care  Other (non-biologic, e.g.	Pain management  Inotropic  Antineoplastic chemotherapy  Immune globulin - IV  Immune globulin - SC  Bleeding disorder  Biologics - Other (monoclonal antibodies,	
Inotropic  Antineoplastic chemotherapy  Immune globulin - IV  Immune globulin - SC  Bleeding disorder  Biologics - Other (monoclonal antibodies, biosimilars, enzymes)  Catheter care  Other (non-biologic, e.g.	Inotropic  Antineoplastic chemotherapy  Immune globulin - IV  Immune globulin - SC  Bleeding disorder  Biologics - Other (monoclonal antibodies,	
Antineoplastic chemotherapy  Immune globulin - IV  Immune globulin - SC  Bleeding disorder  Biologics - Other (monoclonal antibodies, biosimilars, enzymes)  Catheter care  Other (non-biologic, e.g.	Antineoplastic chemotherapy  Immune globulin - IV  Immune globulin - SC  Bleeding disorder  Biologics - Other (monoclonal antibodies,	
chemotherapy  Immune globulin - IV  Immune globulin - SC  Bleeding disorder  Biologics - Other (monoclonal antibodies, biosimilars, enzymes)  Catheter care  Other (non-biologic, e.g.	chemotherapy  Immune globulin - IV  Immune globulin - SC  Bleeding disorder  Biologics - Other (monoclonal antibodies,	
	Immune globulin - SC  Bleeding disorder  Biologics - Other (monoclonal antibodies,	
Bleeding disorder  Biologics - Other (monoclonal antibodies, biosimilars, enzymes)  Catheter care  Other (non-biologic, e.g.	Bleeding disorder  Biologics - Other (monoclonal antibodies,	
Biologics - Other (monoclonal antibodies, biosimilars, enzymes)  Catheter care  Other (non-biologic, e.g.	Biologics - Other (monoclonal antibodies,	
(monoclonal antibodies, biosimilars, enzymes)  Catheter care  Other (non-biologic, e.g.	(monoclonal antibodies,	
Catheter care Other (non-biologic, e.g.		
Catheter care  Other (non-biologic, e.g.	ninsimilars enzymes)	
Other (non-biologic, e.g.		
Other (non-biologic, e.g. steroids, anti-emetics)	Catheter care	
steroius, anti-emetics)		
	Steroius, anti-emetics)	

	of unique patients served in each therapy category in the most rece ients with multiple therapies, please count the patient under each de	
	nts may be counted more than once.	Signated there
Anti-infectives		
,		
Parenteral nutrition		
Hydration		
Pain management		
Inotropic		
Antineoplastic		
chemotherapy		
Immune globulin - IV		
Immune globulin - SC		
Bleeding Disorder		
Biologics - Other (monoclonal antibodies, biosimilars, enzymes)		
Catheter care		
Other (non-biologic, e.g steroids, anti-emetics)		
	down by age category for the home infusion patients served by your nses should equal 100%.	location in 20
Pediatric - Ages 0 to 14		
Adult - Ages 15 - 64		
Older Adult - Ages 65 and older		

(VER 4-) Home Infusion Location Profile				
ontracting and Accounts Receivable				
* 24. Indicate the <u>PERCENTAGE</u> of commercial payer of other methodology. Round answer to the nearest 5%				
AWP				
ASP				
Other				
Comments				
* 25. What was the ratio of bad debt to total net revenue				
Bad debt as a percentage of net revenue	%			
Other (please specify)				

	(VER 4-) Home Infusion Location Profile	
Referral Characterist	tics	
* 26. Indicate the perc	centage of home infusion referrals that were received from each setting d	uring the most
recently completed in	mscar quarter. %	
Hospital/ Acute Care Setting		
Community Physician/Clinic		
Payer		
Skilled Nursing Facility		
Hospice		
Patient/ Self-referred		
Home care nursing agency		
Other		
Comments:		
List in order with the	home infusion medications in terms of revenue dispensed from your locate highest revenue generating drug first.  edications. Do not include self-injectables or oral specialty medications.)	tion in 2018.
Second highest		
Third highest		
Fourth highest		
Fifth highest		

Most dispensed anti-	
infective by volume:	
Second highest	
Third highest	
Fourth highest	
Fifth highest	
•	e diagnosis codes associated with anti-infective patients served by your location in 0-10 code for the primary diagnosis.
Most common diagnosis code.	
Second highest	
Third highest	
rnira nignest	
30. List the top thre	e diagnosis codes associated with parenteral nutrition patients served by your
•	nter the ICD-10 code for the primary diagnosis.
Most common diagnosis	
aada	
code.	
code. Second highest	
Second highest	
Second highest  Third highest  31. List the top thre	e diagnosis codes associated with immune globulin patients served by your location
Second highest  Third highest  31. List the top thre 2018. Enter the ICE	0-10 code for the primary diagnosis.
Second highest  Third highest  31. List the top thre	0-10 code for the primary diagnosis.
Second highest  Third highest  31. List the top thre 2018. Enter the ICE Most common diagnosis code.	0-10 code for the primary diagnosis.
Second highest  Third highest  31. List the top thre 2018. Enter the ICE Most common diagnosis code.  Second highest	0-10 code for the primary diagnosis.
Second highest  Third highest  31. List the top thre 2018. Enter the ICE Most common diagnosis code.	0-10 code for the primary diagnosis.
Second highest  Third highest  31. List the top thre 2018. Enter the ICE Most common diagnosis code.  Second highest  Third highest	0-10 code for the primary diagnosis.
Second highest  Third highest  31. List the top thre 2018. Enter the ICE Most common diagnosis code.  Second highest  Third highest	e diagnosis codes associated with home infused biologics (other than immune globu
Second highest  Third highest  31. List the top thre 2018. Enter the ICE Most common diagnosis code.  Second highest  Third highest	e diagnosis codes associated with home infused biologics (other than immune globucation in 2018. Enter the ICD-10 code for the primary diagnosis.
Second highest  Third highest  31. List the top thre 2018. Enter the ICE Most common diagnosis code.  Second highest  Third highest  32. List the top thre provided by your locations.	e diagnosis codes associated with home infused biologics (other than immune globucation in 2018. Enter the ICD-10 code for the primary diagnosis.
Second highest  Third highest  31. List the top thre 2018. Enter the ICE Most common diagnosis code.  Second highest  Third highest  32. List the top thre provided by your low Most common diagnosis	e diagnosis codes associated with home infused biologics (other than immune globucation in 2018. Enter the ICD-10 code for the primary diagnosis.

# (VER 4-) Home Infusion Location Profile Referral Conversion \* 33. What percentage of all referrals received in the most recently completed fiscal quarter were converted successfully to start of care in the home? Comments: \* 34. Rank the reasons for patients not converting to start of care after being referred to your location from most frequent reason to least frequent. Report on data from the most recently completed fiscal quarter. (1 = Most frequent reason, 12 = least frequent reason) N/A No coverage for home infusion (Medicare payer) ☐ N/A No coverage for home infusion (Commercial payer) N/A No caregiver in the home N/A Out of network with payer source ☐ N/A Vascular access could not be established N/A Out of service area N/A No nurse available ☐ N/A Patient/caregiver unable to learn infusion N/A Drug currently in shortage N/A Unable to source the drug (sole source distribution) N/A Patient safety concern (IV drug abuser, unsafe environment) N/A Therapy discontinued - No need for home infusion N/A Other

04 - 66:	_
Staffin	r
Juli	v

\* 35. Indicate the number full time equivalents (FTE's) working at your home infusion location in each category below. For assistance in calculating your FTE's utilize a free online FTE Employee Calculator. (E.g.) www.healthcare.gov/shop-calculators-fte/)

Enter "0" if your location does not have any employees in a particular category. Do not include per diem staff who are not guaranteed regularly scheduled hours.

Management/Supervisory		
Pharmacists		
Nurses (for making home visits)		
Delivery staff		
Billing staff		
Other professional clinical staff (dietitians, etc.)		
Admissions staff (e.g. insurance verification, nurse liaisons)		
Sales staff		
Pharmacy technicians		
Warehouse staff		
Clerical or office staff		
Administration (information systems, human resources, quality control, accounting, legal, etc.)		
Other		
36. Enter the total sale employer payroll taxe	ary expense associated with the home infusion business for 2018. Descriptions and benefits.	o not include

	CENTAGE of the total salary (not including employer payroll taxes ar	
expenditures spent of	n each staffing category in 2018. Enter "0" if your location does not $\epsilon$	employ staff for a
particular category. F	or multi-site locations with centralized administration functions, indic	ate the percentage
contributed if known.		
		ı
Management/Supervisory		ı
Pharmacists		ı
Pilalillacists		
Nurses (for making home		ı
visits)		
D-1:		ı
Delivery staff		
Billing staff		ı
Other professional clinical		ı
staff		
Admissions staff (e.g.		
insurance verification,		ı
nurse liaisons)		
Sales staff		ı
Sales Stall		
Pharmacy technicians		
,		ı
Warehouse staff		
Administration		
(information systems,		
quality control, human		
resources, accounting,		ı
legal, etc.)		
		ı
Other		

(VER 4-) Home Infusion Location Profile				
Compounding Compliance				
* 38. To what degree does your location comply we described in the United States Pharmacopeia (	with the current (2008) standard for sterile compounding USP) Chapter <797>?			
Meets all, and exceed some requirements  Meets no requirements				
Meets all requirements	Unsure			
Meets most requirements	Our location does not compound sterile medications			
Meets some requirements				
Comment:				

ompounding Activities		
* 39 Does your location current	ly provide compounded hazardous drugs?	
Yes	No	
Comment:		
40. Will your location provide	compounded hazardous drugs after December 1, 2019, when the United	ł
States Pharmacopeia (USP) (	Chapter <800> goes in to effect?	
Yes	No	
Comment:		
	e compounded sterile products from non-sterile source ingredients?	
Yes	○ No	
Comment:		

### Administration Methods

typical month for you	e number of compounded sterile products (CSPs) prepared in each our home infusion location.	categor <u>y<b>in a</b></u>
Enter o il your locati	ion does not prepare a particular category of CSP.	
Syringes		
Bags (non-pump)		
Bags (pump, air- evacuated)		
Parenteral nutrition		
Elastomeric devices		
Binary connector devices (e.g addEase, mini-bag Plus, ADD-vantage)		
Pre-mixes and frozen products		
Other		

# Patient Survey Trends

* 43. How many <u>home infusion</u> patients were discharged by your location in the most rece quarter?	nt complete fiscal
Do not include enteral, self-injectable, or infusion suite patients.	
* 44. How many patient satisfaction surveys did your location administer to home infusion properties and the most recent complete fiscal quarter?	oatients in the
* 45. How many patient satisfaction surveys from <a href="https://home.infusion.patients">home infusion patients</a> were <a href="returned">returned</a> in the complete fiscal quarter?	the most recent

(VER 4-) Home	Infusion	Location	Profile
---------------	----------	----------	---------

#### Outcomes

# (VER 4-) Home Infusion Location Profile Your location is not enrolled in NHIF Benchmarking Unfortunately, your location is not set up to contribute data to NHIF's benchmarking program. Please contact Jennifer Lyons at jennifer.lyons@nhia.org to learn how to obtain a Data Participation Code for your location.

(VER 4-) Home Infusion Location Profile
Thank you
Thank you. You have completed the Benchmarking Location Profile.